In inflammatory bowel disease, ATG16L1 has been shown to inhibit RIPK3-dependent necroptosis, thereby activating mitophagy, maintaining mitochondrial integrity, and reducing inflammation (82). This evidence concerns the gene RIPK3 and inflammatory bowel disease.